US Unfair Trade Investigation: German Pharmaceutical Pricing

Client Update | July 2026

Executive Summary

The United States Trade Representative (USTR) has initiated a Section 301 unfair trade investigation into German pharmaceutical pricing practices. This presents significant implications for manufacturers, healthcare authorities, and policymakers. The law is commonly used to impose import tariffs, although no specific remedy has yet been detailed. Stakeholders are invited to submit comments to USTR by 10 August 2026.

Investigation Scope

USTR alleges that German acts, policies, and practices suppress pharmaceutical pricing below fair market value, forcing American patients to finance a disproportionate share of global research and development (R&D) costs for innovative medicines.

According to USTR, there is a price differential of 3.9x higher pricing for US consumers over German consumers for branded drugs. This figure is provided without context whether the consumers are principally patients, private payors, or government benefit programs. USTR also leaves undefined whether this figure accounts for distinctions in the product mix across the drugs included in the price differential measurement.

Opportunity for Comment to USTR

USTR is seeking submissions on the following matters (deadline: 10 August 2026):

• The German acts, policies, and practices affecting pharmaceutical pricing
• Other German acts, policies, and practices related to underpayment for innovative pharmaceutical products
• Whether the pricing practices are unreasonable or discriminatory
• The nature and extent of burden or restriction on US commerce
• Whether German practices are actionable under Section 301 of the Trade Act
• Recommended remedial actions, including tariff and non-tariff measures

Critical Dates and Deadlines

German Price Control Mechanisms Alleged

The Federal Ministry of Health (Bundesministerium für Gesundheit/BMG), conditions price confidentiality on requirements including a 9% price discount, administrative payment, and rebate program. The rebates will phase in beginning in 2027, although according to USTR they will continue to rise in the coming years.

Rebate Structure

Static Rebate (2027 – First Half)

3.5%

Dynamic Rebate (2027 – Second Half and Beyond)

Formula-based calculation:

(Actual Sales – Target Spend) / (Sales of Innovative Medicines)

USTR states that the dynamic rebate could reach 20% by 2030.

Stakeholder Implications

This investigation affects multiple constituencies in Germany:

Pharmaceutical Manufacturers: Potential exposure to punitive tariffs or trade restrictions if USTR determines that German pricing practices are unreasonable or discriminatory.

German Health Authorities: The investigation challenges the regulatory framework governing pharmaceutical pricing and may lead to bilateral trade negotiations or compensatory measures.

Industry Associations: Organisations representing pharmaceutical interests should consider coordinated submissions to preserve industry competitiveness and domestic regulatory autonomy.

Recommended Actions

Monitor USTR developments: Review updates on the official USTR Section 301 investigation portal.

Consider submitting comments: Stakeholders with substantive input on German pricing policies or their effects should prepare submissions before 10 August.

Coordinate with industry bodies: Industry associations should consider collective submissions to amplify stakeholder positions.

Engage trade counsel: Organisations with significant US exposure should consider engaging specialists in US trade law and Section 301 procedures.

We remain available to discuss the investigation in further detail and to assist with submission preparation.